Radhika Rajan

TL;DR: Residual cancer burden was calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases and was a significant predictor of distant relapse-free survival (DRFS) in multivariate Cox regression analyses.

TL;DR: The data suggest that low tau expression renders microtubules more vulnerable to paclitaxel and makes breast cancer cells hypersensitive to this drug, which may be used as a marker to select patients for pac litaxel therapy.

TL;DR: The authors investigated the contribution of assessing tumor cellularity in the pathologic evaluation of response to chemotherapy and found that accurate measurement of residual tumor size and histopathologic changes within the tumor bed contribute to this outcome.

TL;DR: Randomized trials comparing neoadjuvant versus adjuvant chemotherapy show that primary chemotherapy allows more frequent breast‐preserving surgery even though no survival advantage has been demonstrated.

TL;DR: There is a role for the development of new histologic approaches to augment the pathologic and clinical assessment and provide information on the differential response, particularly for tumors in which less than pathologic complete response is achieved.